Nasdaq · CIK 0001707502
SLDB Solid Biosciences Inc.
Insider trading from SEC Form 4. Last filing 6 d ago. Close $6.87 on Oct 9, 2026, +75% from the 52-week low and -38% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
SLDBOct 9, 2026 · close 6.87
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Solid Biosciences Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Clare Kahn director buy | $9,924 1,860 shares | +169% | - | |
| 53Moderate | Bain Capital Life Sciences Investors, LLC owner buy | $4.0M 1,000,000 shares | +25% | - | |
| 65Notable | Perceptive Advisors LLC director, owner buy | $20M 5,000,000 shares | +73% | - | |
| 50Moderate | Adage Capital Management, L.P. owner buy | $1.9M 252,545 shares | +6% | - | |
| 0Weak | Gabriel Brooks Chief Medical Officer sell | $13k 3,256 shares | -12% | - | |
| 16Weak | Alexander Cumbo President and CEO sell | $45k 11,365 shares | -16% | - | |
| 0Weak | Ilan Ganot director sell | $6,776 1,711 shares | -10% | - | |
| 0Weak | Jessie Hanrahan Chief Regulatory Officer sell | $12k 3,079 shares | -14% | - | |
| 0Weak | Paul Herzich Chief Technology Officer sell | $11k 2,688 shares | -13% | - | |
| 5Weak | David T Howton Chief Operating Officer sell | $22k 5,561 shares | -18% | - | |
| 0Weak | Ilan Ganot director sell | $448 144 shares | -1% | - | |
| 0Weak | Ilan Ganot director sell | $4,551 1,056 shares | -8% | - | |
| 37Weak | Alexander Cumbo President and CEO sell | $62k 11,114 shares | -22% | - | |
| 25Weak | Jessie Hanrahan Chief Regulatory Officer sell | $26k 4,610 shares | -24% | - | |
| 20Weak | Paul Herzich Chief Technology Officer sell | $16k 2,777 shares | -19% | - | |
| 30Weak | David T Howton Chief Operating Officer sell | $28k 5,072 shares | -24% | - | |
| 5Weak | Gabriel Brooks Chief Medical Officer sell | $19k 2,923 shares | -21% | - |
Transactions
The last 57 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Ian F Smith director | MOption exercise Common Stock | +3,440 | - | - | 141,585 | 6 d ago |
| Oct 2, 2026 | Ian F Smith director | MOption exercise Restricted Stock Unitsderivative | -3,440 | $0.00 | $0 | 3,440 | 6 d ago |
| Mar 11, 2025 | Clare Kahn director | POpen-market purchase Common Stock | +1,860 | $5.34 | $9,924 | 2,960 | Mar 13, 2025 |
| Feb 19, 2025 | Bain Capital Life Sciences Investors, LLC owner | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $4.03 | $4.0M | 5,034,582 | Feb 21, 2025 |
| Feb 19, 2025 | Perceptive Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnote | +5,000,000 | $4.03 | $20M | 11,833,539 | Feb 21, 2025 |
| Feb 19, 2025 | Ra Capital Management, L.p. owner | POpen-market purchase Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +3,722,085 | $4.03 | $15M | 3,722,085 | Feb 21, 2025 |
| Feb 19, 2025 | Bain Capital Life Sciences Investors, LLC owner | POpen-market purchase Pre-Funded Warrant (right to buy)derivativeindirect: See footnotes | +6,444,170 | $4.03 | $26M | 6,444,170 | Feb 21, 2025 |
| Feb 18, 2025 | Adage Capital Management, L.P. owner | POpen-market purchase Common Stock, $0.001 par value per shareindirect: See footnotes | +252,545 | $7.56 | $1.9M | 4,248,084 | Feb 19, 2025 |
| Feb 13, 2025 | Paul Herzich Chief Technology Officer | MOption exercise Common Stock10b5-1 | +7,187 | - | - | 21,076 | Feb 18, 2025 |
| Feb 13, 2025 | Jessie Hanrahan Chief Regulatory Officer | MOption exercise Common Stock10b5-1 | +8,125 | - | - | 22,360 | Feb 18, 2025 |
| Feb 13, 2025 | David T Howton Chief Operating Officer | MOption exercise Common Stock10b5-1 | +14,687 | - | - | 30,350 | Feb 18, 2025 |
| Feb 13, 2025 | Ilan Ganot director | MOption exercise Common Stockindirect: Wife10b5-1 | +4,861 | - | - | 16,550 | Feb 18, 2025 |
| Feb 13, 2025 | Alexander Cumbo President and CEO | MOption exercise Common Stock10b5-1 | +30,031 | - | - | 72,082 | Feb 18, 2025 |
| Feb 13, 2025 | Gabriel Brooks Chief Medical Officer | MOption exercise Common Stock10b5-1 | +10,937 | - | - | 26,068 | Feb 18, 2025 |
| Feb 14, 2025 | David T Howton Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -5,561 | $3.96 | $22k | 24,789 | Feb 18, 2025 |
| Feb 14, 2025 | Paul Herzich Chief Technology Officer | SOpen-market sale Common Stock10b5-1 | -2,688 | $3.96 | $11k | 18,388 | Feb 18, 2025 |
| Feb 14, 2025 | Jessie Hanrahan Chief Regulatory Officer | SOpen-market sale Common Stock10b5-1 | -3,079 | $3.96 | $12k | 19,281 | Feb 18, 2025 |
| Feb 14, 2025 | Ilan Ganot director | SOpen-market sale Common Stockindirect: Wife10b5-1 | -1,711 | $3.96 | $6,776 | 14,839 | Feb 18, 2025 |
| Feb 14, 2025 | Alexander Cumbo President and CEO | SOpen-market sale Common Stock10b5-1 | -11,365 | $3.96 | $45k | 60,717 | Feb 18, 2025 |
| Feb 14, 2025 | Gabriel Brooks Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -3,256 | $3.96 | $13k | 22,812 | Feb 18, 2025 |
| Feb 13, 2025 | David T Howton Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -14,687 | $0.00 | $0 | 44,063 | Feb 18, 2025 |
| Feb 13, 2025 | Paul Herzich Chief Technology Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -7,187 | $0.00 | $0 | 21,563 | Feb 18, 2025 |
| Feb 13, 2025 | Gabriel Brooks Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -10,937 | $0.00 | $0 | 32,813 | Feb 18, 2025 |
| Feb 13, 2025 | Jessie Hanrahan Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -8,125 | $0.00 | $0 | 24,375 | Feb 18, 2025 |
| Feb 13, 2025 | Alexander Cumbo President and CEO | MOption exercise Restricted Stock Unitsderivative10b5-1 | -30,031 | $0.00 | $0 | 90,094 | Feb 18, 2025 |
| Feb 13, 2025 | Ilan Ganot director | MOption exercise Restricted Stock Unitsderivativeindirect: Wife10b5-1 | -4,861 | $0.00 | $0 | 14,583 | Feb 18, 2025 |
| Jan 31, 2025 | David T Howton Chief Operating Officer | AGrant or award Restricted Stock Unitsderivative | +169,100 | $0.00 | $0 | 169,100 | Feb 11, 2025 |
| Jan 31, 2025 | Jessie Hanrahan Chief Regulatory Officer | AGrant or award Restricted Stock Unitsderivative | +110,500 | $0.00 | $0 | 110,500 | Feb 11, 2025 |
| Jan 31, 2025 | Ilan Ganot director | AGrant or award Restricted Stock Unitsderivativeindirect: Wife | +60,000 | $0.00 | $0 | 60,000 | Feb 11, 2025 |
| Jan 31, 2025 | Paul Herzich Chief Technology Officer | AGrant or award Restricted Stock Unitsderivative | +98,700 | $0.00 | $0 | 98,700 | Feb 11, 2025 |
| Jan 31, 2025 | Gabriel Brooks Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +112,900 | $0.00 | $0 | 112,900 | Feb 11, 2025 |
| Jan 31, 2025 | Alexander Cumbo President and CEO | AGrant or award Restricted Stock Unitsderivative | +401,600 | $0.00 | $0 | 401,600 | Feb 11, 2025 |
| Jan 27, 2025 | Ilan Ganot director | MOption exercise Common Stockindirect: Wife10b5-1 | +388 | - | - | 11,833 | Jan 29, 2025 |
| Jan 28, 2025 | Ilan Ganot director | SOpen-market sale Common Stockindirect: Wife10b5-1 | -144 | $3.11 | $448 | 11,689 | Jan 29, 2025 |
| Jan 27, 2025 | Ilan Ganot director | MOption exercise Common Stock10b5-1 | +3,883 | - | - | 98,690 | Jan 29, 2025 |
| Jan 27, 2025 | Ilan Ganot director | MOption exercise Restricted Stock Unitsderivativeindirect: Wife10b5-1 | -388 | $0.00 | $0 | 389 | Jan 29, 2025 |
| Jan 27, 2025 | Ilan Ganot director | MOption exercise Restricted Stock Unitsderivative10b5-1 | -3,883 | $0.00 | $0 | 3,884 | Jan 29, 2025 |
| Jan 3, 2025 | Ilan Ganot director | MOption exercise Common Stockindirect: Wife | +2,994 | - | - | 12,501 | Jan 7, 2025 |
| Jan 6, 2025 | Ilan Ganot director | SOpen-market sale Common Stockindirect: Wife | -1,056 | $4.31 | $4,551 | 11,445 | Jan 7, 2025 |
| Jan 3, 2025 | Ilan Ganot director | MOption exercise Restricted Stock Unitsderivativeindirect: Wife | -2,994 | $0.00 | $0 | 5,988 | Jan 7, 2025 |
| Dec 2, 2024 | David T Howton Chief Operating Officer | MOption exercise Common Stock | +13,051 | - | - | 20,735 | Dec 4, 2024 |
| Dec 2, 2024 | Paul Herzich Chief Technology Officer | MOption exercise Common Stock | +7,239 | - | - | 14,959 | Dec 4, 2024 |
| Dec 2, 2024 | Jessie Hanrahan Chief Regulatory Officer | MOption exercise Common Stock | +11,862 | - | - | 18,845 | Dec 4, 2024 |
| Dec 2, 2024 | Alexander Cumbo President and CEO | MOption exercise Common Stock | +28,612 | - | - | 49,598 | Dec 4, 2024 |
| Dec 3, 2024 | David T Howton Chief Operating Officer | SOpen-market sale Common Stock | -5,072 | $5.60 | $28k | 15,663 | Dec 4, 2024 |
| Dec 3, 2024 | Paul Herzich Chief Technology Officer | SOpen-market sale Common Stock | -2,777 | $5.60 | $16k | 12,182 | Dec 4, 2024 |
| Dec 3, 2024 | Jessie Hanrahan Chief Regulatory Officer | SOpen-market sale Common Stock | -4,610 | $5.60 | $26k | 14,235 | Dec 4, 2024 |
| Dec 3, 2024 | Alexander Cumbo President and CEO | SOpen-market sale Common Stock | -11,114 | $5.60 | $62k | 38,484 | Dec 4, 2024 |
| Dec 2, 2024 | Alexander Cumbo President and CEO | MOption exercise Restricted Stock Unitsderivative | -28,612 | $0.00 | $0 | 57,225 | Dec 4, 2024 |
| Dec 2, 2024 | Jessie Hanrahan Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative | -11,862 | $0.00 | $0 | 23,725 | Dec 4, 2024 |
| Dec 2, 2024 | Paul Herzich Chief Technology Officer | MOption exercise Restricted Stock Unitsderivative | -7,239 | $0.00 | $0 | 14,478 | Dec 4, 2024 |
| Dec 2, 2024 | David T Howton Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -13,051 | $0.00 | $0 | 26,103 | Dec 4, 2024 |
| Jun 11, 2024 | Perceptive Advisors LLC director, owner | AGrant or award Director Stock Option (Right to Buy)derivativeindirect: See Footnotes | +34,400 | $0.00 | $0 | 34,400 | Nov 19, 2024 |
| Jun 11, 2024 | Adam Leo Stone director | AGrant or award Director Stock Option (Right to Buy)derivative | +34,400 | $0.00 | $0 | 34,400 | Nov 19, 2024 |
| Oct 18, 2024 | Gabriel Brooks Chief Medical Officer | MOption exercise Common Stock | +9,750 | - | - | 13,902 | Oct 22, 2024 |
| Oct 21, 2024 | Gabriel Brooks Chief Medical Officer | SOpen-market sale Common Stock | -2,923 | $6.50 | $19k | 10,979 | Oct 22, 2024 |
| Oct 18, 2024 | Gabriel Brooks Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -9,750 | $0.00 | $0 | 29,250 | Oct 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Adage Capital Management, L.P.owner
- Bain Capital Life Sciences Investors, LLCowner
- Gabriel BrooksChief Medical Officer
- Alexander CumboPresident and CEO
- Ilan Ganotdirector
- Jessie HanrahanChief Regulatory Officer
- Paul HerzichChief Technology Officer
- David T HowtonChief Operating Officer
- Clare Kahndirector
- Perceptive Advisors LLCdirector, owner
- Ra Capital Management, L.p.owner, director
- Ian F Smithdirector
- Adam Leo Stonedirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.